Adaptive T cell immunotherapy in cancer
Adaptive T cell immunotherapy in cancer
复制标题
癌症的适应性 T 细胞免疫疗法
DOI:
10.1007/s11427-020-1713-9
复制
发表时间:
2020-07
期刊:
影响因子:
--
通讯作者:
Weidong Han
中科院分区:
文献类型:
--
作者:
Dongdong Ti;Miaomiao Bai;Xiaolei Li;Jianshu Wei;Deyun Chen;Zhiqiang Wu;Yao Wang;Weidong Han
Impaired tumor-specific effector T cells contribute to tumor progression and unfavorable clinical outcomes. As a compensatory T cell-dependent cancer immunoediting strategy, adoptive T cell therapy (ACT) has achieved encouraging therapeutic results, and this strategy is now on the center stage of cancer treatment and research. ACT involves theex vivostimulation and expansion of tumor-infiltrating lymphocytes (TILs) with inherent tumor reactivity or T cells that have been genetically modified to express the cognate chimeric antigen receptor or T cell receptor (CAR/TCR), followed by the passive transfer of these cells into a lymphodepleted host. Primed T cells must provide highly efficient and long-lasting immune defense against transformed cells during ACT. Anin-depth understanding of the basic mechanisms of these living drugs can help us improve upon current strategies and design better next-generation T cell-based immunotherapies. From this perspective, we provide an overview of current developments in different ACT strategies, with a focus on frontier clinical trials that offer a proof of principle. Meanwhile, insights into the determinants of ACT are discussed, which will lead to more rational, potent and widespread applications in the future.
登录
查看更多内容
DOI:
10.1007/s11427-018-9411-4
发表时间:
2018-11
期刊:
Sci China Life Sci
影响因子:
--
作者:
遆冬冬;伍志强;付小兵;韩为东
通讯作者:
韩为东
影响因子:
2
作者:
R. Dmochowski
通讯作者:
R. Dmochowski
DOI:
10.1016/j.respe.2020.09.004
发表时间:
2020-10-10
期刊:
Revue D'Epidemiologie et De Sante Publique
影响因子:
--
作者:
La rédaction
通讯作者:
La rédaction
影响因子:
9.3
作者:
通讯作者:
--